Biotech Stock MoonLake Surges 33% After Announcing Positive Outcome From Type B Meeting With U.S. FDA-To The Moon - Tiger Brokers Online Investing Community - To The Moon

4
Comment
Favorite

Biotech Stock MoonLake Surges 33% After Announcing Positive Outcome From Type B Meeting With U.S. FDA

Reuters01-08

MoonLake Immunotherapeutics climbed 33% in the premarket on Thursday after the company said that the FDA will not require additional clinical trials to support a marketing application for its lead candidate, sonelokimab (SLK).

Citing a Type B meeting with the regulator, the Swiss biotech noted that the FDA agreed that without additional trials, its existing VELA-1, VELA-2, and MIRA trials could support a Biologic License Application for SLK in hidradenitis suppurativa, an inflammatory skin condition.

Given the official records of the meeting, the company said it will continue with its plans to submit a BLA for sonelokimab in H2 2026 for HS, which indicates an unmet medical need with a market opportunity expected to reach $15B by 2035.

“The fact that we can prepare the BLA with the wealth of data across the VELA and MIRA trials provides us and the FDA with flexibility to determine the best label possible, so that SLK, if approved, can have the most positive impact for HS patients,” CEO Jorge Santos da Silva added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

4

Report

Comment

empty

No comments yet

Most Discussed

7x24

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2601362465?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 21:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601362465","market":"fut","top_or_hot":-1,"title":"Biotech Stock MoonLake Surges 33% After Announcing Positive Outcome From Type B Meeting With U.S. FDA","media":"Reuters","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/MLTX\">MoonLake Immunotherapeutics</a> climbed 33% in the premarket on Thursday after the company said that the FDA will not require additional clinical trials to support a marketing application for its lead candidate, sonelokimab (SLK).</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/5d3a89ad5142fed169196db585ea6ff6\" tg-width=\"867\" tg-height=\"618\"/></p><p style=\"text-align: left;\">Citing a Type B meeting with the regulator, the Swiss biotech noted that the FDA agreed that without additional trials, its existing VELA-1, VELA-2, and MIRA trials could support a Biologic License Application for SLK in hidradenitis suppurativa, an inflammatory skin condition.</p><p style=\"text-align: left;\">Given the official records of the meeting, the company said it will continue with its plans to submit a BLA for sonelokimab in H2 2026 for HS, which indicates an unmet medical need with a market opportunity expected to reach $15B by 2035.</p><p style=\"text-align: left;\">“The fact that we can prepare the BLA with the wealth of data across the VELA and MIRA trials provides us and the FDA with flexibility to determine the best label possible, so that SLK, if approved, can have the most positive impact for HS patients,” CEO Jorge Santos da Silva added.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech Stock MoonLake Surges 33% After Announcing Positive Outcome From Type B Meeting With U.S. FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech Stock MoonLake Surges 33% After Announcing Positive Outcome From Type B Meeting With U.S. FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-08 21:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/MLTX\">MoonLake Immunotherapeutics</a> climbed 33% in the premarket on Thursday after the company said that the FDA will not require additional clinical trials to support a marketing application for its lead candidate, sonelokimab (SLK).</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/5d3a89ad5142fed169196db585ea6ff6\" tg-width=\"867\" tg-height=\"618\"/></p><p style=\"text-align: left;\">Citing a Type B meeting with the regulator, the Swiss biotech noted that the FDA agreed that without additional trials, its existing VELA-1, VELA-2, and MIRA trials could support a Biologic License Application for SLK in hidradenitis suppurativa, an inflammatory skin condition.</p><p style=\"text-align: left;\">Given the official records of the meeting, the company said it will continue with its plans to submit a BLA for sonelokimab in H2 2026 for HS, which indicates an unmet medical need with a market opportunity expected to reach $15B by 2035.</p><p style=\"text-align: left;\">“The fact that we can prepare the BLA with the wealth of data across the VELA and MIRA trials provides us and the FDA with flexibility to determine the best label possible, so that SLK, if approved, can have the most positive impact for HS patients,” CEO Jorge Santos da Silva added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nRSDB3Y62:1","article_id":"2601362465","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601362465","pubTimestamp":1767879671,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"$MoonLake Immunotherapeutics(MLTX)$ climbed 28% in the premarket on Thursday after the company said that the FDA will not require additional clinical trials to support a marketing application for its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MLTX":"MoonLake Immunotherapeutics"},"translate_title":"Moonlake Immunotherapeutics宣布与美国FDA B型会议取得积极成果后股价飙升28%","themeId":"33791b051befbfd8525af904615f530c","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MLTX":0.9},"content_text":"MoonLake Immunotherapeutics climbed 33% in the premarket on Thursday after the company said that the FDA will not require additional clinical trials to support a marketing application for its lead candidate, sonelokimab (SLK).Citing a Type B meeting with the regulator, the Swiss biotech noted that the FDA agreed that without additional trials, its existing VELA-1, VELA-2, and MIRA trials could support a Biologic License Application for SLK in hidradenitis suppurativa, an inflammatory skin condition.Given the official records of the meeting, the company said it will continue with its plans to submit a BLA for sonelokimab in H2 2026 for HS, which indicates an unmet medical need with a market opportunity expected to reach $15B by 2035.“The fact that we can prepare the BLA with the wealth of data across the VELA and MIRA trials provides us and the FDA with flexibility to determine the best label possible, so that SLK, if approved, can have the most positive impact for HS patients,” CEO Jorge Santos da Silva added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}